CytoDyn to Present Findings on Its Feline Immunodeficiency Virus (FIV) Therapeutic Antibody Program  
10/5/2012 9:57:58 AM

LUTZ, Fla.--(BUSINESS WIRE)--CytoDyn Inc. (the "Company") (CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that it is presenting an update on its Feline Immunodeficiency Virus (FIV) therapeutic antibody program at the 19th West Coast Retrovirus meeting in Palm Springs, California. Dr. Richard Trauger, CytoDyn’s Chief Scientific Officer, will present a poster titled “Influence of anti-LFA-1 on FIV infection ex vivo and in vivo,” describing new preliminary findings regarding CytoFeline™, a feline reactive monoclonal antibody targeting the cell antigen CD11a under development by CytoDyn for the treatment of feline immunodeficiency virus. The work was performed in the laboratories of Dr. John Elder, Professor in the Department of Immunology and Microbial Science at Scripps Research Institute, and Dr. Sue VandeWoude, DVM Associate Dean for Research, CVMBS Professor of Comparative Medicine, DMIP Colorado State University.